I-Mab initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of I-Mab (IMAB) with a Buy rating and $5 price target I-Mab is a clinical-stage biotechnology company focused on precision therapeutics for the treatment of cancer, the analyst tells investors in a research note. The firm believes the company’s CLDN18.2 x 4-1BB bispecific antibody, givastomig, could be a significant value driver for shares, approaching the top-line Phase 1b combination dose escalation and dose expansion data.